Molnupiravir intermediate CAS NO.2346620-55-9

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.
Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.
To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

((3aR,4R,6R,6aR)-6-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylisobutyrate;((3aR,4R,6R,6aR)-6-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3Chemicalbook,4-d][1,3]dioxol-4-yl)methylisobutyrate;URIDINE,2',3'-O-(1-METHYLETHYLIDENE)-,4-OXIMEChemicalbook,5'-(2-METHYLPROPANOATE);Molnupiravirn-1;((3aR,4R,6R,6aR)-6-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3

((3aR,4R,6R,6aR)-6-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate

After the patient takes monabiravir tablets orally, human cells will absorb the drug and then convert it into a basic substance similar to ribonucleic acid (RNA).

Then comes the first stage of the drug's action: RNA polymerase, known as the "virus replicator", will quietly inject these artificial RNA fragments into the virus' genetic material.

In the next second stage, these RNA-like fragments will be ligated into the genetic material of the virus. If the new coronavirus continues to try to replicate itself, it will only replicate variants containing various errors. In the end, the pathogen cannot continue to replicate.

To put it simply, the new crown virus says that I have used all my life to copy myself, why the last copy of myself is not my own, I can't accept it, the new crown pawn.

The above is the mechanism of action of the drug. In order for the drug to have the best effect, it must be taken as soon as possible after infection. Ideally, as soon as the patient tests positive, the drug will be taken orally immediately to limit virus replication as soon as possible.

In the second half of this year, clinical trials will be able to produce results, whether monabiravir is really a good medicine against the new crown. The United States has pre-ordered 1.7 million doses, only waiting for it to obtain a medical license.